The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease

Bibliography

• Catapano AL, Reiner Z, De Backer G, ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217(1):3-46
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Hopkins PN, Toth PP, Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5(3 Suppl):1-8
   PubMedGoogle Scholar
• Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173(1):55-68
   PubMed Web of Science ®Google Scholar
• Nishimura S, Sekiguchi M, Kano T, Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999;144(2):409-17
   PubMed Web of Science ®Google Scholar
• Pijlman AH, Huijgen R, Verhagen SN, Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010;209(1):189-94
   PubMed Web of Science ®Google Scholar
• Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975;1(7918):1208-11
   PubMed Web of Science ®Google Scholar
• Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br Med J (Clin Res Ed) 1985;291(6510):1671-3
   PubMedGoogle Scholar
• Lane DM, McConathy WJ, Laughlin LO, Selective removal of plasma low density lipoprotein with the HELP system: biweekly versus weekly therapy. Atherosclerosis 1995;114(2):203-11
   PubMed Web of Science ®Google Scholar
• Matsuzaki M, Hiramori K, Imaizumi T, Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 2002;40(2):220-7
   PubMed Web of Science ®Google Scholar
• Bundesausschuss G. Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungs- und Behandlungsmethoden der vertragsarztlichen Versorgung. Bundesanzeiger 2010;109:2561
   Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31(23):2844-53
   PubMed Web of Science ®Google Scholar
• Bundesministerium fur Gesundheit. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses uber eine Anderung der Richtlinie Methoden vertragsarztlicher Versorgung: Apherese bei isolierter Lp(a)-Erhohung. 2008
   Google Scholar
• Wierzbicki AS, Hardman T, Viljoen A. New lipid-lowering drugs: an update. Int J Clin Pract 2012;66(3):270-80
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9719):998-1006
   PubMed Web of Science ®Google Scholar
• Akdim F, Visser ME, Tribble DL, Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105(10):1413-19
   PubMed Web of Science ®Google Scholar
• Visser ME, Akdim F, Tribble DL, Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010;51(5):1057-62
   PubMed Web of Science ®Google Scholar
• Parhofer KG. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid 2012;7:29-38
   PubMedGoogle Scholar
• Bell DA, Hooper AJ, Burnett JR. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs 2011;20(2):265-72
   PubMed Web of Science ®Google Scholar
• Stein EA, Dufour R, Gagne C, A randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on therapy in heterozygous familial hypercholesterolemia patients with coronary artery disease. Eur Heart J 2012;31(Suppl 1):abstract
   Google Scholar
• Stein EA, Dufour R, Gagne C, Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012;126(19):2283-92
   PubMed Web of Science ®Google Scholar
• Parhofer KG, Barrett PH, Demant T, Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia. J Lipid Res 1996;37(11):2383-93
   PubMed Web of Science ®Google Scholar
• Parhofer KG, Barrett PH, Demant T. Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B. J Lipid Res 2000;41(10):1596-603
   PubMed Web of Science ®Google Scholar
• Parhofer KG. Lipoprotein(a): medical treatment options for an elusive molecule. Curr Pharm Des 2011;17(9):871-6
   PubMed Web of Science ®Google Scholar
• Visser ME, Kastelein JJ, Stroes ES. Apolipoprotein B synthesis inhibition: results from clinical trials. Curr Opin Lipidol 2010;21(4):319-23
   PubMed Web of Science ®Google Scholar
• Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198(2):247-55
   PubMed Web of Science ®Google Scholar